[go: up one dir, main page]

AU2023427437A1 - 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers - Google Patents

5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers

Info

Publication number
AU2023427437A1
AU2023427437A1 AU2023427437A AU2023427437A AU2023427437A1 AU 2023427437 A1 AU2023427437 A1 AU 2023427437A1 AU 2023427437 A AU2023427437 A AU 2023427437A AU 2023427437 A AU2023427437 A AU 2023427437A AU 2023427437 A1 AU2023427437 A1 AU 2023427437A1
Authority
AU
Australia
Prior art keywords
dimethyltryptamine
methoxy
treatment
mental disorders
breastfeeding mothers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023427437A
Inventor
Conor Burke
Naoise GAFFNEY
Theis Terwey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GH Research Ireland Ltd
Original Assignee
GH Research Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2023/057873 external-priority patent/WO2023186826A1/en
Application filed by GH Research Ireland Ltd filed Critical GH Research Ireland Ltd
Publication of AU2023427437A1 publication Critical patent/AU2023427437A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below.
AU2023427437A 2023-01-30 2023-09-27 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers Pending AU2023427437A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP23153995.8 2023-01-30
EP23153939.6 2023-01-30
EP23153939 2023-01-30
EP23153995 2023-01-30
AUPCT/EP2023/057873 2023-03-27
PCT/EP2023/057873 WO2023186826A1 (en) 2022-03-27 2023-03-27 5-meo-dmt for use in the treatment of postpartum depression
AUPCT/EP2023/057883 2023-03-27
PCT/EP2023/057883 WO2023186835A1 (en) 2022-03-27 2023-03-27 Treatment of mental disorders
PCT/EP2023/076816 WO2024160389A1 (en) 2023-01-30 2023-09-27 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers

Publications (1)

Publication Number Publication Date
AU2023427437A1 true AU2023427437A1 (en) 2025-09-18

Family

ID=88206855

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2023426967A Pending AU2023426967A1 (en) 2023-01-30 2023-09-27 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
AU2023427437A Pending AU2023427437A1 (en) 2023-01-30 2023-09-27 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2023426967A Pending AU2023426967A1 (en) 2023-01-30 2023-09-27 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression

Country Status (6)

Country Link
KR (2) KR20250139377A (en)
CN (2) CN120813348A (en)
AU (2) AU2023426967A1 (en)
IL (2) IL322428A (en)
MX (2) MX2025008728A (en)
WO (2) WO2024160390A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4155306A1 (en) 2021-01-15 2023-03-29 Beckley Psytech Limited Neuroactive ergoline analogue
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (en) 1998-01-29 1999-10-14 Markus Storz Inhaler for generating vapors containing aroma and / or active substances from plant material and / or liquids
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
JP2007516404A (en) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド Optically or electrically ignited built-in heating unit and drug supply unit using the same
ES2355983T3 (en) 2006-08-01 2011-04-01 STOBI GMBH & CO. KG BALL VALVE FOR INHALERS.
US20220071958A1 (en) 2019-02-22 2022-03-10 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression
EP4464377A3 (en) * 2019-02-22 2025-02-26 GH Research Ireland Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
EP3868364A1 (en) * 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
US11406619B2 (en) * 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations

Also Published As

Publication number Publication date
KR20250139377A (en) 2025-09-23
KR20250135903A (en) 2025-09-15
AU2023426967A1 (en) 2025-09-18
CN120712084A (en) 2025-09-26
IL322429A (en) 2025-09-01
MX2025008728A (en) 2025-10-01
WO2024160390A1 (en) 2024-08-08
CN120813348A (en) 2025-10-17
IL322428A (en) 2025-09-01
WO2024160389A1 (en) 2024-08-08
MX2025008755A (en) 2025-11-03

Similar Documents

Publication Publication Date Title
AU2023427437A1 (en) 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers
AU2023427992A1 (en) Treatment of mental disorders
Farver et al. Zolpidem for antipsychotic-induced parkinsonism
US20080090896A1 (en) Strontium-Based Treatment Of Otosclerosis
Choi et al. Cerebral salt wasting treated with fludrocortisone in a 17-year-old boy
Kim et al. Dilated cardiomyopathy in a 2 month-old infant: a severe form of hypocalcemia with vitamin d deficient rickets
Csonka Long-term aspect of treatment with metronidazole (flagyl) in trichomonal vaginitis
Fine Choosing a treatment modality for the infant, child and adolescent with endstage renal disease
Saade Clonazepam/stiripentol
Akgül et al. How Did a Child With 71.3% Carboxy-Haemoglobin Survive?
McEvitt TREATMENT OF RESPIRATORY OBSTRUCTION IN MICRO-GNATHIA BY USE OF A NASOGASTRIC TUBE
Żurowska et al. Peritonitis in 203 children treated with peritoneal dialysis In Poland during 2000-2003
Fukumura Mouth ulcer and elevation of serum lactate dehydrogenase: case report
WO2025221229A1 (en) Audible and automatic dropper device for use for babies of visually impaired parents or guardians
Teil Pyrimethamine/sulfadoxine
Pasha Various toxicities: 3 case reports
Jopling Antileprosy drugs
Villarroel First-use syndrome in patients treated with hollow-fiber dialyzers
Sasson Nausea: case report
Bain Levetiracetam/lisinopril/methotrexate interaction
Blissit Clozapine/fluphenazine
Pericleous et al. P. 7. c. 010 The cost effectiveness of aripiprazole for the treatment of adolescents with schizophrenia
Hong Seizure, listlessness, altered sleep, lethargy: 3 case reports
Claus Colistin/tobramycin interaction
Maqsood Aggravation of constipation: case report